As biologics grow more complex, so do the tools required to understand, validate, and ensure their quality. From monoclonal antibody cocktails to antibody-drug conjugates (ADCs) and cell therapies, developers are navigating new frontiers in potency, purity, and functional characterization. Promega’s R&D scientists have been actively contributing to this evolving dialogue through respected industry platforms like […] The post At the Forefront of Biologics Characterization: Insights from ...
